Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate covid-19 at high risk for disease progression: a prospective cohort study

HIGHLIGHTS

• who: Alessia Savoldi from the Laboratory analyses were conducted in a subgroup of , patientsSequencing was successfully performed in , (88%) patients. Among them, patients were infected by the B.1.1., (Alpha, UK) variant, while two patients were infected by B.11.462. Both are sub-lineages of the B [1]. European clade, but not directly related with each other. Anti-SARS-Co, IgGs were successfully quantified in , patients: , (26%), (64%) and , (10%) received bamlanivimab, bamlanivimab-etesevimab and casirivimabimdevimab, respectively (Appendix Table, ). No significant differences were observed among the three different arms of treatment regarding the vaccination status . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.